Aztreonam
Authors:
- 8 July 1986
- journal article
- review article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 6 (4) , 138-149
Abstract
Aztreonam is a new, totally synthetic beta‐lactamase agent — the first monobactam. It is highly resistant to hydrolytic inactivation caused by plasmid‐mediated (except PSE‐2 enzyme found in some Pseudomonas species) or chromosomally mediated beta‐lactamases (except for K1 produced by rare strains of Klebsiella oxytoca). Accordingly, aztreonam remains active against many pathogens that are resistant to other beta‐lactam antibiotics. The drug exhibits directed antibacterial activity against gram‐negative organisms and is effective as monotherapy against most Enterobacteriaceae and Hemophilus and Neisseria species, including beta‐lactamase‐producing strains; it is not active against anaerobes or gram‐positive organisms. Before culture results are known, it may be necessary to administer the agent empirically in combination with other antibiotics. Aztreonam is rapidly distributed to most body tissues and fluids when administered parenterally. Its serum half‐life is 1.7 hours, suggesting a dosing interval of 6–8 hours for severe or life‐threatening infections and 8–12 hours for moderately severe infections and urinary tract infections. It is primarily eliminated unchanged in the urine and in much lesser amounts as a microbiologically inactive metabolite; slight biliary excretion may occur. Aztreonam is well‐tolerated, lacking any serious adverse hematologic, otic, or renal system effects. Its lack of effect on anaerobes helps to maintain resistance against colonization. Particularly in light of its safety and unique properties, aztreonam promises to be a useful alternative to aminoglycoside therapy.Keywords
This publication has 46 references indexed in Scilit:
- Aztreonam: Antibacterial Activity, β-Lactamase Stability, and Interpretive Standards and Quality Control Guidelines for Disk-Diffusion Susceptibility TestsClinical Infectious Diseases, 1985
- Aztreonam—An OverviewDrug Intelligence & Clinical Pharmacy, 1985
- Aztreonam: The first monobactamThe American Journal of Medicine, 1985
- In vitro activity of aztreonam in combination with newer beta-lactams and amikacin against multiply resistant gram-negative bacilliAntimicrobial Agents and Chemotherapy, 1984
- In vitro activities of aztreonam, piperacillin, and ticarcillin combined with amikacin against amikacin-resistant Pseudomonas aeruginosa and P. cepacia isolates from children with cystic fibrosisAntimicrobial Agents and Chemotherapy, 1984
- In vitro activity of azthreonam, a monobactam antibioticAntimicrobial Agents and Chemotherapy, 1982
- In vitro antagonism of beta-lactam antibiotics by cefoxitinAntimicrobial Agents and Chemotherapy, 1982
- Comparative in vitro study of SQ26,776Antimicrobial Agents and Chemotherapy, 1982
- Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic gram-negative bacteriaAntimicrobial Agents and Chemotherapy, 1982
- In vitro and in vivo antibacterial effects of combinations of beta-lactam antibioticsAntimicrobial Agents and Chemotherapy, 1981